Latest Safety News

Page 16 of 252
Elementos has materially strengthened its balance sheet while moving its Spanish Oropesa tin project closer to permitting, financing and a final investment decision. The annual report also highlights a doubling of Cleveland’s inferred tungsten resource, but both projects still require substantial capital and further approvals.
Maxwell Dee
Maxwell Dee
21 Sept 2026
Nyrada has secured AU$12.0 million from institutional and sophisticated investors, with a further AU$2.0 million shareholder purchase plan planned, giving the biotech funding to advance its Xolatryp clinical programs. The raise also carries substantial dilution and an unusually large proposed director subscription worth AU$5.125 million, subject to shareholder approval.
Ada Torres
Ada Torres
21 Sept 2026
Neurotech International has dosed the first patient in its pivotal Phase 3 Beyond Harmony study of NTI164, moving the autism therapy into its most consequential clinical test yet. The trial plans to enrol up to 200 children across six Australian sites, but no Phase 3 efficacy data are available at this stage.
Ada Torres
Ada Torres
21 Sept 2026
Telix will acquire ITM in a proposed US$1.65 billion deal that combines a commercial radioisotope supplier with Telix’s precision medicine and therapeutic pipeline. The transaction could give Telix greater supply-chain control and entry into a validated cancer treatment market, but it also brings dilution, integration risk and an unresolved FDA pathway for ITM-11.
Ada Torres
Ada Torres
21 Sept 2026
Epiminder has enrolled the 75th patient in its DETECT study, meeting its September target as the US site network expands to 21 centres. The company expects to reach 100 enrolments in November and remains focused on completing the 210-patient study by the end of the first half of calendar 2027.
Ada Torres
Ada Torres
17 Sept 2026
Patrys has formed an international Clinical Advisory Committee to help shape the next stages of RLS-2202, its injectable quetiapine candidate for delirium in acute-care settings. The appointments add recognised expertise in delirium research, intensive care and trial design, but do not yet provide clinical efficacy or regulatory evidence.
Ada Torres
Ada Torres
17 Sept 2026
Emyria has presented its regulated Australian psychedelic-treatment experience to the US FDA, putting clinical delivery systems rather than drug development at the centre of its US ambitions. The appearance raises the company’s profile, but does not yet disclose regulatory approval, a commercial agreement or a financial commitment.
Ada Torres
Ada Torres
16 Sept 2026
EBR Systems plans to file a Changes Being Effected PMA supplement in the fourth quarter to make echo-induced pacing risks and their mitigations more prominent on WiSE System labelling. The FDA has aligned with the proposed path, but the filing and final labelling changes are still ahead.
Victor Sage
Victor Sage
16 Sept 2026
PolyNovo delivered 16.1% revenue growth and a sharp improvement in operating cash flow in FY26, despite a lower statutory profit after a prior-year tax benefit and a fire-related write-off. The ASX-listed wound-care company now expects to lodge its U.S. PMA application for NovoSorb BTM before the end of 2026.
Victor Sage
Victor Sage
15 Sept 2026
Tivan has secured a 50 km² exploration concession immediately north of its Turiscai project in Timor-Leste, subject to formal regulatory grant. The addition would lift the project to eight licences covering approximately 394 km² ahead of planned maiden drilling in the fourth quarter.
Maxwell Dee
Maxwell Dee
14 Sept 2026
Titomic has secured a US$5.0 million contract to install and commission its TKF 1000 cold spray system at the U.S. Air Force’s Tinker Air Force Base. Delivery is scheduled for the third quarter of 2027, subject to site coordination and approvals.
Victor Sage
Victor Sage
14 Sept 2026
Entropy Neurodynamics reported that all six patients in Cohort 1 of its Phase 2 BED trial maintained clinically meaningful improvement 12 weeks after two TRP-8803 infusions. Three patients experienced no binge-eating episodes during the 84-day follow-up, although the results come from a small, open-label study without a control group.
Ada Torres
Ada Torres
14 Sept 2026

Browse the archive

Full archive